Drugs / NNC0361-0041
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04279613 | Nov 2020 → Aug 2023 | type 1 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0361-0041 | “A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041” NCT04279613 ↗ |
| Modality | Other / unclassified | “novel plasmid expressing preproinsulin2 and a combination of immune-modulatory cytokines” PMID 34957480 ↗ Aug 2021 |
| Route | Subcutaneous | “administered s.c. via syringe and needle” NCT04279613 ↗ |